Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide.
about
Clinical usefulness of novel serum and imaging biomarkers in risk stratification of patients with stable anginaBiomarkers of acute myocardial infarction in the elderly: troponin and beyondCoagulation, inflammation and myocardial dysfunction in unstable coronary artery disease and the influence of glycoprotein IIb/IIIa inhibition and low molecular weight heparinCritical appraisal of C-reactive protein throughout the spectrum of cardiovascular diseaseGuidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of CardiologyGene expression profiling reveals potential prognostic biomarkers associated with the progression of heart failureTherapeutic impact of follistatin-like 1 on myocardial ischemic injury in preclinical modelsPoint-of-care diagnostics for niche applications.Correlation between plaque composition as assessed by virtual histology and C-reactive protein.Sensitive and rapid quantification of C-reactive protein using quantum dot-labeled microplate immunoassay.Acute coronary syndromes: diagnosis and management, part IB-type natriuretic peptide and ischemia in patients with stable coronary disease: data from the Heart and Soul study.Novel antibody markers of unstable atherosclerotic lesions.B-type natriuretic peptide is a long-term predictor of all-cause mortality, whereas high-sensitive C-reactive protein predicts recurrent short-term troponin T positive cardiac events in chest pain patients: a prognostic studyChange in growth differentiation factor 15, but not C-reactive protein, independently predicts major cardiac events in patients with non-ST elevation acute coronary syndrome.Biomarkers in acute myocardial infarction.B-type natriuretic peptide levels predict extent and severity of coronary artery disease in non-ST elevation acute coronary syndrome and normal left ventricular function.Ability of salivary biomarkers in the prognostic of systemic and buccal inflammation.Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18.Clinical criteria replenish high-sensitive troponin and inflammatory markers in the stratification of patients with suspected acute coronary syndrome.Utility of salivary biomarkers for demonstrating acute myocardial infarction.Comparison of multiplex immunoassay platforms.Identifying patients at high risk of a cardiovascular event in the near future: current status and future directions: report of a national heart, lung, and blood institute working group.C-reactive Protein as a Predictor of Adverse outcome in Patients with Acute Coronary Syndrome.B-type natriuretic peptide and high sensitive C-reactive protein predict 2-year all cause mortality in chest pain patients: a prospective observational study from Salta, ArgentinaProteome expression and carbonylation changes during Trypanosoma cruzi infection and Chagas disease in rats.Role of biomarkers in risk stratification of acute coronary syndromeThe role of B-type and other natriuretic peptides in health and disease.Testing of low-risk patients presenting to the emergency department with chest pain: a scientific statement from the American Heart Association.The emerging role of metabolomics in the development of biomarkers for pulmonary hypertension and other cardiovascular diseases (2013 Grover Conference series)The role of brain natriuretic peptide in the prediction of cardiac performance in coronary artery bypass grafting.Biomarkers in drug discovery and development: from target identification through drug marketing.Using bacterial biomarkers to identify early indicators of cystic fibrosis pulmonary exacerbation onsetMetabolomic profiling for the identification of novel biomarkers and mechanisms related to common cardiovascular diseases: form and function.BNP was associated with ischemic myocardial scintigraphy and death in patients at chest pain unitIntegrated metabolomics and genomics: systems approaches to biomarkers and mechanisms of cardiovascular disease.C reactive protein for risk stratification in acute coronary syndromes? Verdict: unprovenPrognostic relations between inflammatory markers and mortality in diabetic patients with non-ST elevation acute coronary syndrome.Changes in the activity of connective tissue matrix enzymes in the metabolic syndrome.Adrenomedullin concentrations at two time points following myocardial infarction and prediction of mid-term outcomes.
P2860
Q26859111-FE773A36-EA5D-4DA9-AC4C-925170DBBF03Q27005967-875D623D-6BC2-4A8E-9B8E-A5923F76049AQ28208874-14B19720-11BE-434C-9701-A9F608B8BCC5Q28219483-0BFFE010-0C4E-451D-9734-DF0AA68F5D22Q28239975-A5276564-9CAC-4410-AA07-C1EE211DD06FQ28262080-3EB55018-D508-4D29-BFE1-87E30A87C5DCQ28273799-C0355A23-B37B-434B-B47B-FC712161E424Q30357499-36D0393A-24C6-4CAA-8AB4-2A2854AD46CCQ30438725-68A18CE0-058D-4698-9F6E-1701503A4773Q30469757-6434740B-486B-4FCB-AD95-892FE0C8101AQ30490718-22992A02-B68F-4517-9587-68893495D498Q30885744-76018852-A2BA-4B79-BD78-8079EB18E729Q33355013-5B328EB6-8272-441B-AAE4-67E57DA3D0C1Q33387034-8C6DC82A-9A90-4C7B-AB86-24E061A2005DQ33563146-2FB330B7-7754-49A5-A3BD-B66004262F0EQ33596823-B74924C5-8F36-446A-B40A-8BE4F890C68FQ33596861-86BE98C3-F103-4FA9-943E-2734C15AB300Q33676905-D65FEE44-4BB6-460C-BBA0-283378DAD48DQ33691730-CA870466-BFB9-4EE9-AFAE-4AE638AACBA5Q33706806-97EED32A-17DF-4376-AE2A-2703C818C004Q33936565-706C7473-AEE4-4900-A139-576538F9230CQ34002687-59A744B4-504C-4D75-968B-AA0BC30054FBQ34002717-BC530151-4C11-456E-9009-8521FA3004EDQ34032614-1CE08319-ACC2-4D54-89AD-6FD3468DC180Q34035094-8CCBF471-BE57-4CE2-8C39-FBAAE0CCD218Q34112124-695A8CE9-AF60-48DD-B1F9-42524F8D3755Q34530136-7D22F450-38DF-45F4-B192-BF1832D363BAQ34566491-1F47AD3A-7330-45E3-A30C-1DA8A4B46540Q34604478-40FBAE7B-BF58-4F86-A3EB-BD409A535020Q34782469-64EA92E3-4101-41E1-9DB1-A1E8E3037DF3Q34796770-F03B5F2D-2275-46EE-8C03-B3D5A30ACEADQ35118033-2B21EFF5-E1FD-438A-A0BF-5168AA668FE3Q35143420-8564D6E9-6154-40E9-923E-D2049A152A18Q35219088-57263D0E-C4DB-4E3D-8BD5-6FE587A41AB7Q35292436-946AD45B-776F-4726-BD24-4FBCFCE29849Q35534297-176A09A0-2410-4C84-BF10-EF732DAA67DAQ35581735-F1B2EEEC-93FD-4820-9E13-D7321D558EBFQ35582120-DAE88690-DD25-42C7-B517-8C252CFC0C89Q35674263-32385CC9-213F-4A07-B348-47EB4301153BQ35691363-1A66D98B-F43E-4367-8004-AD763DAD09B0
P2860
Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Multimarker approach to risk s ...... nd B-type natriuretic peptide.
@en
Multimarker approach to risk s ...... nd B-type natriuretic peptide.
@nl
type
label
Multimarker approach to risk s ...... nd B-type natriuretic peptide.
@en
Multimarker approach to risk s ...... nd B-type natriuretic peptide.
@nl
prefLabel
Multimarker approach to risk s ...... nd B-type natriuretic peptide.
@en
Multimarker approach to risk s ...... nd B-type natriuretic peptide.
@nl
P2093
P1433
P1476
Multimarker approach to risk s ...... nd B-type natriuretic peptide.
@en
P2093
C Michael Gibson
Carolyn McCabe
Christopher P Cannon
David A Morrow
James A de Lemos
Marc S Sabatine
Nader Rifai
Sabina A Murphy
P304
P356
10.1161/01.CIR.0000015464.18023.0A
P407
P577
2002-04-01T00:00:00Z